The purpose of this study was to look at current developments in epidemiological research, diagnostic approaches, and therapeutic therapy of local allergic rhinitis (LAR) in adults and children. The body of evidence for LAR is expanding, particularly in paediatric and Asian populations. In both children and adults, the prevalence of LAR is lower in Asian countries than in Western countries. LAR is a chronic disease and a distinct rhinitis phenotype that affects up to 26.5 percent of nonatopic rhinitis sufferers. The illness rapidly worsens clinically, with the emergence of asthma and conjunctivitis, severely reducing the patient’s quality of life. The Nasal Allergen Provocation Test is the gold standard for diagnosis, and it can be supplemented by a basophil activation test and the detection of particular IgE in nasal secretions.
Allergen immunotherapy improves clinical symptoms and quality of life in LAR patients significantly and quickly. LAR is a prevalent condition, with varying frequency depending on geography. In children and adults with rhinitis, LAR must be included in the differential diagnosis. The diagnosis of LAR is critical in order to begin etiologic treatment, such as allergen immunotherapy, which has been shown to be highly successful in these individuals.
